Ken Reali, former Senior Vice President and General Manager of Smith & Nephew’s Biologics and Spine Business, is TranS1’s new president and COO.
TranS1’s New President/COO: Ken Reali
1 min read Premium comments
Rick Randall, company CEO made the announcement on January 7.
Randall said Reali’s, “significant experience and proven track record in orthopedics, spine and biologics will be invaluable as we continue to advance beyond our AxiaLIF minimally invasive approach to lumbar fusion.”
In addition to his tenure at Smith & Nephew, Reali has over 20 years of general management, sales and marketing experience with leading medical device and orthopedic companies. Prior to Smith & Nephew, Reali held positions with Stryker and Biomet.
Reali commented,
I have had a chance to observe TranS1’s products in the market and believe the minimally invasive approach provides surgeons and patients with many unique advantages relative to other lumbar fusion surgeries. I look forward to working with the Trans1 team to continue to expand its market presence in spinal implants.
One of Reali’s first tasks will likely be to obtain a category I CPT code for the AxiaLIF procedure and working with customers on reimbursement issues.
TranS1 currently markets two single-level fusion products, the AxiaLIF and the AxiaLIF 360, and a two-level fusion product, the AxiaLIF 2L, in the U.S. and Europe. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.